Product News | FDA Approved Drugs for Cancer Treatment

• share:
• 
• 
• 
• 
• 
• 

Cancer cells grow and divide out of control, and spread into surrounding tissues, causing genetic changes. Tobacco use, age and family history, human papillomavirus (HPV), overweight and obesity, and alcohol consumption are found be risk factors for cancer. 

The International Agency for Research on Cancer (IARC) reported about 19.3 million new cases and 10.0 million deaths in 2020. There will be an estimation of 28.4 million in 2040.

 

Anti-cancer drug targets

Small molecule cancer drugs have been widely studied since the last decade. Among drug targets of anti-cancer drugs approved in the U.S., DNA targeting drugs which stops cancer from repairing its DNA ranks first, following by G-protein-coupled receptors (GR) and estrogen receptors (ERs). Androgen receptor (AR) is the fourth most popular drug target and tyrosine-protein kinase (KIT) is the fifth. 

 

Recent FDA approved anti-cancer drugs

In January, 2023, Pirtobrutinib (Jaypirca) and Elacestrant (Orserdu) are two New Molecular Entity (NME) drug to treat cancer. Pirtobrutinib is used for relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor, that was granted accelerated approval by FDA due to the overall response rate (ORR) and duration of response (DOR). Elacestrant is used to treat postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

 

In 2022, there are NME anti-cancer drugs approved. These include Adagrasib (KRAZATI), Olutasidenib (REZLIDHIA), Futibatinib (LYTGOBI), Ganaxolone (ZTALMY), and Pacritinib (VONJO). Adagrasib is a RAS GTPase family inhibitor for adult patients with KRAS G12C¬-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Olutasidenib capsules are used for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation. Futibatinib is for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 gene fusions or other rearrangements. Ganaxolone marks for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder, also known as CDD, in patients aged 2 years and older. Pacritinib is a kinase inhibitor indicated for the treatment of adults with intermediate or high-risk primary or secondary myelofibrosis with a platelet count below 50 × 109 /L. 

 

 

 

 

Source: FDA Drug Approvals and Databases

Cancer cells grow and divide out of control, and spread into surrounding tissues, causing genetic changes. Tobacco use, age and family history, human papillomavirus (HPV), overweight and obesity, and alcohol consumption are found be risk factors for cancer.

 

The International Agency for Research on Cancer (IARC) reported about 19.3 million new cases and 10.0 million deaths in 2020. There will be an estimation of 28.4 million in 2040.

 

 

Anti-cancer drug targets

Small molecule cancer drugs have been widely studied since the last decade. Among drug targets of anti-cancer drugs approved in the U.S., DNA targeting drugs which stops cancer from repairing its DNA ranks first, following by G-protein-coupled receptors (GR) and estrogen receptors (ERs). Androgen receptor (AR) is the fourth most popular drug target and tyrosine-protein kinase (KIT) is the fifth.

 

 

Recent FDA approved anti-cancer drugs

In January, 2023, Pirtobrutinib (Jaypirca) and Elacestrant (Orserdu) are two New Molecular Entity (NME) drug to treat cancer. Pirtobrutinib is used for relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor, that was granted accelerated approval by FDA due to the overall response rate (ORR) and duration of response (DOR). Elacestrant is used to treat postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

In 2022, there are NME anti-cancer drugs approved. These include Adagrasib (KRAZATI), Olutasidenib (REZLIDHIA), Futibatinib (LYTGOBI), Ganaxolone (ZTALMY), and Pacritinib (VONJO). Adagrasib is a RAS GTPase family inhibitor for adult patients with KRAS G12C¬-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Olutasidenib capsules are used for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation. Futibatinib is for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 gene fusions or other rearrangements. Ganaxolone marks for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder, also known as CDD, in patients aged 2 years and older. Pacritinib is a kinase inhibitor indicated for the treatment of adults with intermediate or high-risk primary or secondary myelofibrosis with a platelet count below 50 × 109 /L.

 

 

Source: FDA Drug Approvals and Databases